NCT05159518: A Study of PRT2527 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: If patients have HER2+ breast cancer, they only qualify for this trial if the cancer also expresses a MYC mutation; Patients with TNBC or ER+ breast cancer are not required to also have a MYC mutation
Exclusions: Patients with uncontrolled central nervous system (CNS) metastases; Patients with prior exposure to a CDK9 inhibitor

Comments are closed.

Up ↑